# Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose

> **NCT02017327** · PHASE4 · COMPLETED · sponsor: **Laboratoires Thea** · enrollment: 379 (actual)

## Conditions studied

- Primary Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Monoprost
- **DRUG:** Lumigan 0.01%
- **DRUG:** Lumigan 0.03% Unit Dose

## Key facts

- **NCT ID:** NCT02017327
- **Lead sponsor:** Laboratoires Thea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 379 (ACTUAL)
- **Last updated:** 2020-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02017327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02017327, "Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02017327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*